Duration of Enoxaparin for DVT Prophylaxis in Cellulitis

Evidence-Based Duration Guidelines

The American College of Chest Physicians recommends that enoxaparin should be continued for 6-21 days or until full mobility is restored or hospital discharge, whichever comes first, for patients hospitalized with cellulitis requiring DVT prophylaxis, based on moderate-quality evidence from multiple randomized controlled trials 1, 2, 3
Standard duration ranges from 6-21 days during hospitalization, based on moderate-quality evidence from multiple randomized controlled trials 1, 2, 3
Continue enoxaparin until full mobility is restored or hospital discharge, whichever occurs first, based on moderate-quality evidence from multiple randomized controlled trials 1, 2, 3
A minimum duration of 7-10 days is recommended for most hospitalized medical patients, based on evidence from multiple sources 4

The American College of Chest Physicians recommends enoxaparin 40 mg subcutaneously once daily as the prophylactic dose, which has proven efficacy in reducing symptomatic DVT and fatal PE in acutely ill, hospitalized, immobilized medical patients 1, 2, 3, 4
This dosing has proven efficacy in reducing symptomatic DVT and fatal PE in acutely ill, hospitalized, immobilized medical patients 1, 2, 3

Prophylaxis is still indicated for high-risk patients with cellulitis who have additional VTE risk factors, including age ≥40 years 2, active cancer 6, previous VTE 7, severe immobilization 7, and obesity (BMI ≥40 kg/m²) 5
The American College of Chest Physicians recommends considering prophylaxis for patients with these risk factors 1, 2, 3

For obese patients (BMI ≥40 kg/m²), consider 40 mg subcutaneously every 12 hours or weight-based dosing of 0.5 mg/kg every 12 hours, based on recommendations from Praxis Medical Insights 5, 6
For severe renal impairment (CrCl <30 mL/min), reduce dose to 30 mg subcutaneously once daily, based on recommendations from Praxis Medical Insights 5, 6, 8

For selected high-risk patients with cellulitis, consider extended prophylaxis with a duration of 14-30 days post-discharge, based on evidence from the Journal of Thrombosis and Haemostasis 7
This applies particularly to patients with multiple VTE risk factors, elevated D-dimer (>2 times upper limit of normal), or IMPROVE VTE score ≥4, based on evidence from the Journal of Thrombosis and Haemostasis 7

Do not discontinue prophylaxis prematurely before mobility is restored, even if clinical improvement of cellulitis occurs, based on recommendations from the American College of Chest Physicians 1, 2, 3
Do not use standard dosing in severe renal impairment without dose reduction, as this increases bleeding risk, based on recommendations from Praxis Medical Insights 5, 6
Do not forget to assess bleeding risk before initiating prophylaxis, particularly in patients with active gastroduodenal ulcer, recent bleeding, or platelet count <50 × 10⁹/L, based on recommendations from the American College of Chest Physicians 3